Posted in | News | Nanoelectronics | Nanoenergy

Electrovaya Receives License Payment for Battery Production in Norway

Electrovaya announces that it has received from Miljobil an initial payment of US $1.3 million as partial consideration for a technology license enabling battery and electric car production at a new plant in Norway. Electrovaya is partnering with Miljobil to produce batteries and electric cars in Norway and providing its proprietary and award winning Lithium Ion SuperPolymer® battery technology to give Miljobil's four-door electric vehicles excellent range and highway speed. The zero emission electric vehicles will be sold in Europe and globally.

"We are delighted to develop a world-leading electric vehicle for the European and Global markets with Miljobil" said Dr. Sankar Das Gupta, Chairman of Electrovaya. "The demand for long range highway speed electric vehicles is large and we expect Electrovaya's battery to be the enabling technology to bring Electric Vehicles into commercial success." Dr. Das Gupta continues "Electrovaya's lithium ion Superpolymer® battery has an unparalleled combination of energy density and power density which is necessary to give electric vehicles both long driving range on a single charge as well as acceleration and high speed capabilities."

"Miljobil is delighted to license Electrovaya's technology and bring Miljobil's vision of electric cars to the global market" said Bjorn Nenseth, CEO of Miljobil. "Miljobil has over the years pioneered the use of Electric vehicles in Norway and we are pleased to announce this new development in our ongoing partnership with Electrovaya."

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.